TrialBMC cancer2016

Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.

Perparim Limani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.